Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Psychiatry
Volume 2015 (2015), Article ID 325061, 6 pages
http://dx.doi.org/10.1155/2015/325061
Case Report

Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases

1Biomedical Centre for Autism Research and Treatment, 70126 Bari, Italy
2Institute of Biosciences and Bioresources, National Research Council of Italy, 80128 Naples, Italy
3Department of Experimental Medicine, Second University of Naples, Via S. Maria di Costantinopoli, 80138 Naples, Italy
4Centre for Autism-La Forza del Silenzio, 81036 Caserta, Italy
5Cancellautismo-No Profit Association for Autism Care, 50132 Florence, Italy

Received 30 June 2015; Revised 15 September 2015; Accepted 16 September 2015

Academic Editor: Masaru Mimura

Copyright © 2015 Nicola Antonucci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Masi, D. S. Quintana, N. Glozier, A. R. Lloyd, I. B. Hickie, and A. J. Guastella, “Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis,” Molecular Psychiatry, vol. 20, pp. 440–446, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. O. Zerbo, C. Yoshida, J. K. Grether et al., “Neonatal cytokines and chemokines and risk of Autism Spectrum Disorder: the Early Markers for Autism (EMA) study: a case-control study,” Journal of Neuroinflammation, vol. 11, article 113, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. R. H. Mitchell and B. I. Goldstein, “Inflammation in children and adolescents with neuropsychiatric disorders: a systematic review,” Journal of the American Academy of Child & Adolescent Psychiatry, vol. 53, no. 3, pp. 274–296, 2014. View at Publisher · View at Google Scholar
  4. S. Gupta, “Immunological treatments for autism,” Journal of Autism and Developmental Disorders, vol. 30, no. 5, pp. 475–479, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Boris, C. C. Kaiser, A. Goldblatt et al., “Effect of pioglitazone treatment on behavioral symptoms in autistic children,” Journal of Neuroinflammation, vol. 4, article 3, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. J. F. Miller and R. S. Chapman, “The relation between age and mean length of utterance in morphemes,” Journal of Speech, Language, and Hearing Research, vol. 24, no. 2, pp. 154–161, 1981. View at Publisher · View at Google Scholar · View at Scopus
  7. J. D. Lewis, A. Ferrara, T. Peng et al., “Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study,” Diabetes Care, vol. 34, no. 4, pp. 916–922, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Keppel Hesselink, “Evolution in pharmacologic thinking around the natural analgesic palmitoylethanolamide: from nonspecific resistance to PPAR-α agonist and effective nutraceutical,” Journal of Pain Research, vol. 6, pp. 625–634, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Aloe, A. Leon, and R. Levi-Montalcini, “A proposed autacoid mechanism controlling mastocyte behaviour,” Agents and Actions, vol. 39, no. 1, pp. C145–C147, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Jyonouchi, L. Geng, A. Ruby, and B. Zimmerman-Bier, “Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention,” Neuropsychobiology, vol. 51, no. 2, pp. 77–85, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. S. J. Walker, J. Fortunato, L. G. Gonzalez, and A. Krigsman, “Identification of unique gene expression profile in children with regressive autism spectrum disorder (ASD) and ileocolitis,” PLoS ONE, vol. 8, no. 3, Article ID e58058, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. L. de Magistris, V. Familiari, A. Pascotto et al., “Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives,” Journal of Pediatric Gastroenterology and Nutrition, vol. 51, no. 4, pp. 418–424, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Borrelli, B. Romano, S. Petrosino et al., “Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent,” British Journal of Pharmacology, vol. 172, no. 1, pp. 142–158, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. G. M. Raso, R. Russo, A. Calignano, and R. Meli, “Palmitoylethanolamide in CNS health and disease,” Pharmacological Research, vol. 86, pp. 32–41, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Mašek, F. Perlík, J. Klíma, and R. Kahlich, “Prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory tract infections,” European Journal of Clinical Pharmacology, vol. 7, no. 6, pp. 415–419, 1974. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Kahlich, J. Klíma, F. Cihla et al., “Studies on prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory infections. Serologically controlled field trials,” Journal of Hygiene Epidemiology Microbiology and Immunology, vol. 23, no. 1, pp. 11–24, 1979. View at Google Scholar · View at Scopus
  17. V. Plesník, M. Havrlantová, J. Jancová, J. Januska, and O. Macková, “Impulsin in the prevention of acute respiratory diseases in school children,” Cesko-Slovenska Pediatrie, vol. 32, no. 6, pp. 365–369, 1977. View at Google Scholar · View at Scopus
  18. D. Wiedermannová, D. Wiedermann, and J. Lokaj, “Prophylactic administration of impulsin to clinically healthy children. Effect on the serum proteins and metabolic activity of granulocytes,” Casopis Lekaru Ceskych, vol. 117, no. 33, pp. 1030–1034, 1978. View at Google Scholar · View at Scopus
  19. T. C. Theoharides, A. Angelidou, K.-D. Alysandratos et al., “Mast cell activation and autism,” Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1822, no. 1, pp. 34–41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. S. D. Skaper, L. Facci, and P. Giusti, “Mast cells, glia and neuroinflammation: partners in crime?” Immunology, vol. 141, no. 3, pp. 314–327, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Schopler and M. E. Van Bourgondien, Childhood Autism Rating Scale, CARS-2, 2nd edition, 2010, http://www.wpspublish.com/.
  22. B. Rimland and M. Edelson, Autism Treatment Evaluation Checklist, Autism Research Institute, San Diego, Calif, USA, 1999, http://autismeval.com/ari-atec/report1.html.
  23. D. A. Geier, J. K. Kern, and M. R. Geier, “A comparison of the autism treatment evaluation checklist (ATEC) and the childhood autism rating scale (CARS) for the quantitative evaluation of autism,” Journal of Mental Health Research in Intellectual Disabilities, vol. 6, no. 4, pp. 255–267, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Kato, H. Kamiya, N. Koide et al., “Spironolactone inhibits production of proinflammatory mediators in response to lipopolysaccharide via inactivation of nuclear factor-κB,” Immunopharmacology and Immunotoxicology, vol. 36, no. 3, pp. 237–241, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. J. J. Bradstreet, S. Smith, D. Granpeesheh, J. M. El-Dahr, and D. Rossignol, “Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders,” Medical Hypotheses, vol. 68, no. 5, pp. 979–987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. J. J. Bradstreet, N. Sych, N. Antonucci et al., “Efficacy of fetal stem cell transplantation in autism spectrum disorders: an open-labeled pilot study,” Cell Transplantation, vol. 23, supplement 1, pp. 105–112, 2014. View at Publisher · View at Google Scholar
  27. Y.-T. Lv, Y. Zhang, M. Liu et al., “Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism,” Journal of Translational Medicine, vol. 11, article 196, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Asadabadi, M.-R. Mohammadi, A. Ghanizadeh et al., “Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial,” Psychopharmacology, vol. 225, no. 1, pp. 51–59, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Siniscalco, A. Sapone, C. Giordano et al., “Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders,” Journal of Autism and Developmental Disorders, vol. 43, no. 11, pp. 2686–2695, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Matsumura, “Leu7 (HNK-1)-positive cells in peripheral blood and natural killer cell activity in patients with atopic dermatitis,” Nippon Hifuka Gakkai Zasshi, vol. 100, no. 1, pp. 57–62, 1990. View at Google Scholar · View at Scopus
  31. W. Wehrmann, U. Reinhold, S. Kukel, N. Franke, M. Uerlich, and H. W. Kreysel, “Selective alterations in natural killer cell subsets in patients with atopic dermatitis,” International Archives of Allergy and Applied Immunology, vol. 92, no. 3, pp. 318–322, 1990. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Hauer, G. Schelling, H. Gola et al., “Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder,” PLoS ONE, vol. 8, no. 5, Article ID e62741, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Tsuboi, N. Takezaki, and N. Ueda, “The N-acylethanolamine-hydrolyzing acid amidase (NAAA),” Chemistry & Biodiversity, vol. 4, no. 8, pp. 1914–1925, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Luongo, R. Russo, C. Avagliano et al., “Galactosyl prodrug of palmitoylethanolamide: synthesis, stability, cell permeation and cytoprotective activity,” European Journal of Pharmaceutical Sciences, vol. 62, pp. 33–39, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Baio, Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators, Centers for Disease Control and Prevention (CDC), Atlanta, Ga, USA, 2014.
  36. Centers for Disease Control and Prevention, “Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2010,” Morbidity and Mortality Weekly Report: Surveillance Summaries, vol. 63, no. 2, pp. 1–21, 2014. View at Google Scholar